MCKENSSON Reports Fiscal 2016 Second-Quarter Results

Release Date: Thursday, October 29, 2015 6:30 am CDT

Terms:

- **Revenue**: $48.8 billion for the second quarter, up 10%
- **Second-quarter GAAP earnings per diluted share from continuing operations**: $2.65, up 29%
- **Second-quarter Adjusted Earnings per diluted share of $3.31**, up 19%
- **Consolidated results include a pre-tax gain of $51 million**, or 14 cents per diluted share, from the sale of our ZEE Medical business.
- **Board of Directors authorized a new $2 billion share repurchase program**.

**Fiscal 2016 Outlook**: Adjusted Earnings per diluted share of $12.50 to $13.00.

SAN FRANCISCO--(BUSINESS WIRE)--Mckesson Corporation (NYSE: MCK) today reported that revenues for the second quarter ended September 30, 2015 were $48.8 billion, up 10% compared to $44.2 billion a year ago. On a constant currency basis, revenues increased 14% over the prior year. On the basis of U.S. generally accepted accounting principles (“GAAP”), second-quarter earnings per diluted share from continuing operations was $2.65 compared to $2.05 a year ago.

Second-quarter Adjusted Earnings per diluted share was $3.31, up 19% compared to $2.79 a year ago. On a constant currency basis, Adjusted Earnings per diluted share increased 20% over the prior year. Second-quarter results include a pre-tax gain of $51 million, or 14 cents per diluted share, related to the sale of the ZEE Medical business within the Distribution Solutions segment. Second-quarter results also reflect lower than expected tax expense driven by a discrete tax benefit of $25 million, or 11 cents per diluted share.

For the first half of the fiscal year, Mckesson generated cash from operations of $1.3 billion, and ended the quarter with cash and cash equivalents of $5.4 billion. During the first half of the fiscal year, Mckesson repurchased nearly $500 million of its common stock, repaid $408 million in long-term debt, had internal capital spending of $274 million and paid $114 million in dividends.

At its recent meeting, Mckesson’s Board of Directors authorized a new $2 billion share repurchase program.

"Mckesson delivered solid results during the first six months of our fiscal year. In addition to the strong operating performance across our businesses in the second quarter, we repurchased approximately 2.5 million shares totaling nearly $500 million, announced the acquisition of the UK pharmacy operations of Savioz's and the acquisition of the pharmaceutical distribution business of United Drug Group in Ireland. At its recent meeting, our Board of Directors also authorized a new $2 billion share repurchase program and we remain exceptionally well positioned to continue to execute our capital management approach to capital deployment. We were also pleased to be selected by Albertsons as its pharmaceutical sourcing and distribution partner across all of its U.S. brands. I am confident in the strength and scale of our global value proposition for our customers and our manufacturing partners, and I am excited about the opportunities across our diversified portfolio of businesses," said John H. Hammergren, chairman and chief executive officer.

"We are updating our full-year outlook and now expect Adjusted Earnings per diluted share of $12.50 to $13.00 for the fiscal year ending March 31, 2016," concluded Hammergren.

**Segment Results**

Distribution Solutions revenues were $48.9 billion for the quarter, up 11% on a reported basis and up 14% on a constant currency basis.

North America pharmaceutical distribution and services revenues were $48.6 billion for the quarter, up 16% on a reported basis and 17% on a constant currency basis. North America revenue growth primarily reflects market growth and our mix of business.

International pharmaceutical distribution and services revenues were $5.9 billion for the quarter, down 13% on a reported basis and up 2% on a constant currency basis.

Medical-Surgical distribution and services second-quarter revenues were up 3% for the quarter, driven by market growth.

In the second quarter, Distribution Solutions GAAP operating profit was $926 million and GAAP operating margin was 1.93%. Second-quarter adjusted operating profit was $1.1 billion, up 8% on a reported basis and up 11% on a constant currency basis, primarily driven by growth in our North America pharmaceutical distribution and services revenues and a pre-tax gain of $51 million from the sale of the ZEE Medical business. Adjusted operating margin for the Distribution Solutions segment was 2.9%.

Technology Solutions second-quarter revenues were $721 million, down 6% compared to the prior year, primarily driven by the completed sale of our nurse triage business in our first quarter and by the anticipated year-over-year decline in our hospital software business, partially offset by growth in our other technology businesses.

Technology Solutions GAAP operating profit was $146 million and Adjusted operating profit was $157 million for the second quarter and Adjusted operating margin was 21.78%.

**Fiscal 2016 Outlook**

Mckesson expects Adjusted Earnings per diluted share between $12.50 and $13.00 for the fiscal year ending March 31, 2016, based on an exchange rate of $1.10 per Euro. The updated full-year outlook reflects a number of items, including the sale of ZEE Medical in the second quarter, the impact of the recently completed $500 million share repurchase program, and a reduction in our full-year adjusted tax rate from 31.5% to 31%, primarily driven by a favorable discrete tax item recognized in the second quarter. The revised guidance range also reflects the expiration of the Optum contract at the start of our fiscal year and our assumption that generic pricing trends will remain weak in the second half of the fiscal year and similar to the level of the second quarter.

The updated outlook for Adjusted Earnings per diluted share between $12.50 and $13.00 excludes the following GAAP items:

- Amortization of acquisition-related intangible assets of $1.25 per diluted share.
- Acquisition expenses and related adjustments of $33 per diluted share.
- LIFO inventory-related charges of 9 cents to 9 cents per diluted share.

The Fiscal 2016 guidance range does not include any potential new capital or litigation reserve adjustments, or the impact of any potential new acquisitions and divestitures, and impairments or material restructuring charges.

**Adjusted Earnings**

Mckesson separately reports financial results on the basis of Adjusted Earnings, a non-GAAP financial measure defined as GAAP income from continuing operations, excluding amortization of equipment-related intangible assets, acquisition expenses and related adjustments, certain capital and litigation reserve adjustments reflecting changes to the company’s reserves for controlled substance distribution claims and average wholesale price litigation matters, and last-in-first-out (“LIFO”) inventory-related adjustments. A reconciliation of Mckesson’s GAAP financial results to Adjusted Earnings is provided in Schedules 2, 3 and 4 of the financial statement tables included in this release.

**Constant Currency**

Mckesson also presents its financial results on a Constant Currency basis. The company conducts business worldwide in local currencies, including Euro, British pound and Canadian dollar. As a result, the comparability of the financial results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. Constant Currency information is presented to provide a framework for assessing the underlying business results performed excluding the effect of foreign currency exchange rate fluctuations. The supplemental Constant Currency information of the company’s GAAP financial results and Adjusted Earnings (Non-GAAP) is provided in Schedule 3 of the financial statement tables included with this release.

**Risk Factors**

Except for historical information contained in this press release, matters discussed may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These statements may be identified by their use of forward-looking terminology such as "believes," "expects," "anticipates," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates" or the negative of these words or other comparable terminology. The discussion of financial and other projections, estimates and targets included in this press release are based on assumptions made by Mckesson and are subject to many factors and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied.

These factors include, but are not limited to, changes in the U.S. healthcare industry and regulatory environment; international operations; changes in the Canadian healthcare industry and regulatory environment; exposure to European economic conditions, including recent austerity measures taken by certain European governments; changes in the European regulatory environment with respect to privacy and data protection regulations; foreign currency fluctuations; the company's ability to compete in the U.S. and international markets, financial results, material adverse change in capital markets, competition, substantial defaults in payment, or a material reduction in payments by, or the loss of, a large customer or group purchasing organization; the loss of government contracts as a result of compliance or bidding failures; public health issues in the U.S. or abroad; malfunction, failure or breach of sophisticated internal information systems to perform as designed; cyber attacks or other privacy or data security incidents; the adequacy of insurance to cover property loss or liability claims; the company’s failure to attract and retain customers for its software products and solutions due to integration and implementation challenges, or due to an inability to keep pace with technological advances; the company’s proprietary products and services may not be adequately protected, and its products or solutions could be found to infringe on the rights of third parties; system errors or failure of our technology products and solutions to conform to specifications; disaster or other event causing interruption of customer access to data residing in our service centers; the delay or extension of our sales or implementation cycles for external software products; changes in circumstances that could impair our goodwill or intangible assets; new or revised tax legislation or challenges to our tax positions, general economic conditions, including changes in the financial markets that may affect the availability and cost of credit to the company, its customers or suppliers; changes in accounting principles generally accepted in the United States of America; and withdrawal from participation in multi-employer pension plans or other retirement and health benefit plans if we are found to have underfunded liabilities. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, the company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or if any of these events or circumstances were to change.

The company has scheduled a conference call for 8:30AM ET. The dial-in number for individuals wishing to participate on the call is 719-234-7317. Erin Lampert, senior vice president, Investor Relations, is...
Schedule 1

MCKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP
(unaudited)
(in millions, except per share amounts)

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30</th>
<th></th>
<th>Six Months Ended September 30</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015</td>
<td>2014</td>
<td>Change</td>
<td>2015</td>
</tr>
<tr>
<td>Revenues</td>
<td>$48,761</td>
<td>$44,160</td>
<td>$4,601</td>
<td>$96,307</td>
</tr>
<tr>
<td>Cost of sales (3) (2)</td>
<td>$(45,917)</td>
<td>$(41,296)</td>
<td>$(4,621)</td>
<td>$(90,615)</td>
</tr>
<tr>
<td>Gross profit</td>
<td>$2,844</td>
<td>$2,864</td>
<td>$(20)</td>
<td>$5,692</td>
</tr>
<tr>
<td>Operating expenses (5) (4)</td>
<td>$(1,890)</td>
<td>$(2,077)</td>
<td>$(187)</td>
<td>$(3,807)</td>
</tr>
<tr>
<td>Operating income</td>
<td>954</td>
<td>787</td>
<td>$167</td>
<td>$1,885</td>
</tr>
<tr>
<td>Other income, net</td>
<td>17</td>
<td>22</td>
<td>$(5)</td>
<td>30</td>
</tr>
<tr>
<td>Interest expense</td>
<td>(91)</td>
<td>(95)</td>
<td>$(4)</td>
<td>(180)</td>
</tr>
<tr>
<td>Income from continuing operations before income taxes</td>
<td>880</td>
<td>714</td>
<td>$166</td>
<td>1,735</td>
</tr>
<tr>
<td>Income tax expense (5)</td>
<td>(244)</td>
<td>(223)</td>
<td>$(21)</td>
<td>(500)</td>
</tr>
<tr>
<td>Income from continuing operations after tax</td>
<td>636</td>
<td>491</td>
<td>$145</td>
<td>1,235</td>
</tr>
<tr>
<td>Loss from discontinued operations, net of tax</td>
<td>(6)</td>
<td>(14)</td>
<td>$(8)</td>
<td>(16)</td>
</tr>
<tr>
<td>Net income</td>
<td>630</td>
<td>477</td>
<td>$153</td>
<td>1,219</td>
</tr>
<tr>
<td>Earnings attributable to noncontrolling interests</td>
<td>(13)</td>
<td>(8)</td>
<td>$(5)</td>
<td>(26)</td>
</tr>
<tr>
<td>Net income attributable to McKesson Corporation</td>
<td>$617</td>
<td>$469</td>
<td>$32%</td>
<td>$1,193</td>
</tr>
</tbody>
</table>

Earnings (loss) per common share attributable to McKesson Corporation (6)

<table>
<thead>
<tr>
<th></th>
<th>Diluted</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuing operations</td>
<td>$2.65</td>
<td>$2.05</td>
<td>$(0.59)</td>
<td>$5.15</td>
</tr>
<tr>
<td>Discontinued operations</td>
<td>$(0.02)</td>
<td>$(0.06)</td>
<td>$(0.04)</td>
<td>$(0.07)</td>
</tr>
<tr>
<td>Total</td>
<td>$2.63</td>
<td>$1.99</td>
<td>$(0.60)</td>
<td>$5.08</td>
</tr>
</tbody>
</table>

Basic

<table>
<thead>
<tr>
<th></th>
<th>Continuing operations</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>$2.66</td>
<td>$2.02</td>
<td>$(0.60)</td>
<td>$5.15</td>
</tr>
</tbody>
</table>

Dividends declared per common share

<table>
<thead>
<tr>
<th></th>
<th>Weighted average common shares</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Diluted</td>
<td>$0.28</td>
<td>$0.24</td>
<td></td>
<td>$0.52</td>
</tr>
<tr>
<td>Basic</td>
<td>235</td>
<td>235</td>
<td></td>
<td>235</td>
</tr>
</tbody>
</table>

(1) Distribution Solutions segment results for the second quarter and first six months of fiscal year 2016 and 2015 include charges of $91 million and $182 million and $94 million and $192 million related to our last-in-first-out ("LIFO") method of accounting for inventories, and for the first six months of fiscal year 2016 include $59 million cash proceeds representing our share of antitrust legal settlements.

(2) Technology Solutions segment results for the first six months of fiscal year 2015 reflect a non-cash pre-tax charge of $34 million primarily related to depreciation and amortization expense due to the reclassification of the workforce business within our International Technology business from discontinued operations to continuing operations. The charge was primarily recorded in cost of sales.

(3) Distribution Solutions segment results for the second quarter and first six months of fiscal year 2016 include a pre-tax gain of $51 million ($33 million after-tax) and $51 million ($29 million after-tax) recognized from the sale of our ZEE Medical business.

(4) Technology Solutions segment results for the first six months of fiscal year 2016 include a pre-tax gain of $51 million ($38 million after-tax) recognized from the sale of our nurse triage business.

(5) The second quarter and first six months of fiscal year 2016 include a $25 million tax benefit related to the reversal of a tax reserve.

(6) Certain computations may reflect rounding adjustments.

Schedule 2

MCKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)
(unaudited)
(in millions, except per share amounts)

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30</th>
<th></th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Vs. Prior Quarter</td>
</tr>
<tr>
<td>Diluted</td>
<td>$0.28</td>
<td>$0.24</td>
<td>$0.52</td>
</tr>
<tr>
<td>Basic</td>
<td>235</td>
<td>235</td>
<td>235</td>
</tr>
</tbody>
</table>

(1) Distribution Solutions segment results for the second quarter and first six months of fiscal year 2016 and 2015 include charges of $91 million and $182 million and $94 million and $192 million related to our last-in-first-out ("LIFO") method of accounting for inventories, and for the first six months of fiscal year 2016 include $59 million cash proceeds representing our share of antitrust legal settlements.

(2) Technology Solutions segment results for the first six months of fiscal year 2015 reflect a non-cash pre-tax charge of $34 million primarily related to depreciation and amortization expense due to the reclassification of the workforce business within our International Technology business from discontinued operations to continuing operations. The charge was primarily recorded in cost of sales.

(3) Distribution Solutions segment results for the second quarter and first six months of fiscal year 2016 include a pre-tax gain of $51 million ($33 million after-tax) and $51 million ($29 million after-tax) recognized from the sale of our ZEE Medical business.

(4) Technology Solutions segment results for the first six months of fiscal year 2016 include a pre-tax gain of $51 million ($38 million after-tax) recognized from the sale of our nurse triage business.

(5) The second quarter and first six months of fiscal year 2016 include a $25 million tax benefit related to the reversal of a tax reserve.

(6) Certain computations may reflect rounding adjustments.
### RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)

#### (unaudited)

<table>
<thead>
<tr>
<th></th>
<th>Gross profit</th>
<th>Operating expenses (1)</th>
<th>Other income, net</th>
<th>Interest expense</th>
<th>Income from continuing operations before income taxes</th>
<th>Income tax expense</th>
<th>Income from continuing operations after tax</th>
<th>Other income, net</th>
<th>Operating expenses (2)</th>
<th>Gross profit</th>
</tr>
</thead>
<tbody>
<tr>
<td>As Reported (GAAP)</td>
<td>$ 2,844</td>
<td>$ 1,890</td>
<td>$ 17</td>
<td>$ 91</td>
<td>$ 880</td>
<td>$ 17</td>
<td>$ 711</td>
<td>$ 235</td>
<td>$ 636</td>
<td>$ 2,844</td>
</tr>
<tr>
<td>Adjusted Earnings (Non-GAAP)</td>
<td>$ 2,938</td>
<td>(1,751)</td>
<td>17</td>
<td>(91)</td>
<td>880</td>
<td>(223)</td>
<td>813</td>
<td>235</td>
<td>636</td>
<td>2,938</td>
</tr>
<tr>
<td>%</td>
<td>(1)</td>
<td>(7)</td>
<td>1</td>
<td>(4)</td>
<td>4</td>
<td>(23)</td>
<td>29</td>
<td>29</td>
<td>22</td>
<td>(1)</td>
</tr>
</tbody>
</table>

#### Diluted earnings per common share from continuing operations, net of tax, attributable to McKesson Corporation (3)

|                                | $ 2.65       | $ 0.10                 | $ -               | $ 0.24           | $ 2.79                                               | $ 0.10             | $ 29                                      | 29                | 29                     |

#### Diluted weighted average common shares

|                                | 235          | 235                    | 235               | 235             | 235                                                  | 235                | 235                                       | 235               | 235                    |

---

(1) Fiscal year 2016 includes a pre-tax gain of $51 million ($33 million after-tax) recognized from the sale of our ZEE Medical business within our Distribution Solutions segment.

(2) Fiscal year 2016 includes a $25 million tax benefit related to the reversal of a tax reserve.

(3) Certain computations may reflect rounding adjustments.

(4) Adjusted Earnings per share on a Constant Currency basis for the second quarter of fiscal year 2016 was $3.34 per diluted share, which excludes the foreign currency exchange effect of $0.03 per diluted share.

For more information relating to the Adjusted Earnings (Non-GAAP) and Constant Currency (Non-GAAP) definitions, refer to the section entitled "Supplemental Non-GAAP Financial Information" of this release.

---

### Schedule 28

**MCKESSON CORPORATION**

**RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED EARNINGS (NON-GAAP)**

**(unaudited)**

**(in millions, except per share amounts)**

<table>
<thead>
<tr>
<th></th>
<th>Six Months Ended September 30, 2015</th>
<th>Change Vs. Prior Period</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>As Reported (GAAP)</td>
<td>Adjusted Earnings (Non-GAAP)</td>
</tr>
<tr>
<td></td>
<td>Amortization of Acquisition - Related Intangibles</td>
<td>Amortization of Acquisition - Related Intangibles</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Gross profit (2)</td>
<td>$ 5,692</td>
<td>$ 4</td>
</tr>
<tr>
<td>Operating expenses (2) (3)</td>
<td>(3,807)</td>
<td>216</td>
</tr>
<tr>
<td>Other income, net</td>
<td>30</td>
<td>1</td>
</tr>
<tr>
<td>Interest expense</td>
<td>(180)</td>
<td></td>
</tr>
<tr>
<td>Income from continuing operations before income taxes</td>
<td>1,735</td>
<td>221</td>
</tr>
<tr>
<td>Income tax expense (4)</td>
<td>(500)</td>
<td>70</td>
</tr>
<tr>
<td>Income from continuing operations after tax</td>
<td>1,235</td>
<td>151</td>
</tr>
</tbody>
</table>

---

(2) Fiscal year 2016 includes a pre-tax gain of $51 million ($33 million after-tax) recognized from the sale of our ZEE Medical business within our Distribution Solutions segment.

(3) Fiscal year 2016 includes a $25 million tax benefit related to the reversal of a tax reserve.

(4) Certain computations may reflect rounding adjustments.

(5) Adjusted Earnings per share on a Constant Currency basis for the second quarter of fiscal year 2016 was $3.34 per diluted share, which excludes the foreign currency exchange effect of $0.03 per diluted share.

For more information relating to the Adjusted Earnings (Non-GAAP) and Constant Currency (Non-GAAP) definitions, refer to the section entitled "Supplemental Non-GAAP Financial Information" of this release.
McKesson Corporation

RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) (unaudited) (in millions)

<table>
<thead>
<tr>
<th>Quarter Ended September 30, 2015</th>
<th>Quarter Ended September 30, 2014</th>
<th>GAAP</th>
<th>Non-GAAP</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>----------------------</td>
<td>----------------------</td>
<td>----------------------</td>
<td>----------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>REVENUES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distribution Solutions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>North America pharmaceutical distribution &amp; services</td>
<td>$40,603</td>
<td>$ -</td>
<td>$40,603</td>
<td>$35,147</td>
</tr>
<tr>
<td>International pharmaceutical distribution &amp; services</td>
<td>5,866</td>
<td>-</td>
<td>5,866</td>
<td>6,714</td>
</tr>
<tr>
<td>Medical-Surgical distribution &amp; services</td>
<td>1,571</td>
<td>-</td>
<td>1,571</td>
<td>1,529</td>
</tr>
<tr>
<td>Total Distribution Solutions</td>
<td>48,040</td>
<td>-</td>
<td>48,040</td>
<td>43,390</td>
</tr>
<tr>
<td>Technology Solutions / Products and Services</td>
<td>721</td>
<td>-</td>
<td>721</td>
<td>770</td>
</tr>
<tr>
<td>Revenues</td>
<td>$48,761</td>
<td>$ -</td>
<td>$48,761</td>
<td>$44,160</td>
</tr>
</tbody>
</table>

GROSS PROFIT

(1) Fiscal year 2016 reflects $59 million of cash proceeds representing our share of antitrust legal settlements within our Distribution Solutions segment.
(2) Fiscal year 2016 includes a pre-tax gain of $51 million ($29 million after-tax) recognized from the sale of our ZEE Medical business within our Distribution Solutions segment.
(3) Fiscal year 2016 includes a pre-tax gain of $51 million ($38 million after-tax) recognized from the sale of our nurse triage business within our Technology Solutions segment.
(4) Fiscal year 2016 includes a $25 million tax benefit related to the reversal of a tax reserve.
(5) Certain computations may reflect rounding adjustments.
(6) Technology Solutions segment results for fiscal year 2015 reflect a non-cash pre-tax charge of $34 million primarily relating to depreciation and amortization expense due to the reclassification of the workforce business within our International Technology business from discontinued operations to continuing operations. The charge was primarily recorded in cost of sales.
(7) Adjusted Earnings per share on a Constant Currency basis for the first six months of fiscal year 2016 was $6.52 per diluted share, which excludes the foreign currency exchange effect of $0.08 per diluted share.

For more information relating to the Adjusted Earnings (Non-GAAP) and Constant Currency (Non-GAAP) definitions, refer to the section entitled "Supplemental Non-GAAP Financial Information" of this release.
Solutions Distribution
Total distribution & Surgical Medical-
services International services distribution & pharmaceutical North America Solutions Distribution
release.
For more information relating to the Adjusted Earnings (Non-GAAP) Technology Distribution profit as a % Operating
STATISTICS taxes before income Income from Expense Operating NET Corporate Solutions Solutions Technology Solutions Distribution expenses

Operating expenses (1) Solutions $ (1,890) $ 139 (1,751) $ (2,077) $ 190 (1,887) $ (118) (2,008) $ 110 $ (1,861) (9) (7) (3)

OTHER INCOME, NET
Distributions Solutions $ 13 - $ 13 $ 17 (1) $ 16 $ 1 $ 14 $ 2 $ 15 (24) (19) (18)
Technology Solutions - - - 2 - 2 - - - - (100) (100) (100) (1)
Corporate 4 - 4 3 - 3 4 4 33 33 33
Other income, net

Operating Profit
Distributions Solutions $ 926 $ 222 $ 1,348 $ 790 $ 269 $ 1,059 $ 17 $ 943 $ 26 $ 1,174 $ 17 $ 8 $ 19
Technology Solutions 146 11 157 125 14 139 (6) 140 (6) 151 $ 17 $ 13 $ 12
Operating profit Corporate 1,072 233 1,305 915 283 1,198 11 1,083 20 1,325 17 9 18
Interest Expense
Income from continuing operations before income taxes

Statistics Operating profit as a % of revenues
Distributions Solutions 1.93 % 2.39 % 1.82 % 2.44 % 1.91 % 2.37 % 11 bp (5) bp 9 bp
Technology Solutions 20.25 21.78 16.23 18.05 19.34 20.86 402 373 311 1

(2) Fiscal year 2016 includes a pre-tax gain of $51 million ($33 million after-tax) recognized from the sale of our ZEE Medical business.

For more information relating to the Adjusted Earnings (Non-GAAP) and Constant Currency (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.

Schaub

MCKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) (unaudited) (in millions)

Six Months Ended September 30, 2015 Six Months Ended September 30, 2014 GAAP Non-GAAP Change

As Adjusted Adjusted As Adjusted Foreign Foreign As Adjusted Adjusted Constant Const
Revenues
Distribution Solutions $ 80,135 $ - $ 80,135 $ 69,451 $ - $ 69,451 $ 746 $ 80,881 $ 746 $ 80,881 $ 15 % 15 % 15 % 2
North America pharmaceutical distribution & services $ 11,704 $ - $ 11,704 $ 13,739 $ - $ 13,739 $ 2,122 $ 13,827 $ 2,123 $ 13,827 (15) (15) 1
International pharmaceutical distribution & services $ 3,011 $ - $ 3,011 $ 2,908 $ - $ 2,908 $ 1 $ 3,012 $ 1 $ 3,012 4 4 4
Medical- Surgical distribution & services Total Distribution Solutions $ 94,850 $ - $ 94,850 $ 86,098 $ - $ 86,098 $ 2,870 97,720 $ 2,870 $ 97,720 10 10 12 1

Schedule 3B

Earnings (Non-GAAP)
Change
As Adjusted Adjusted Constant Const
Revenues Distribution Solutions $ 1,148 $ 286 $ 972 $ 1 (1) (1) 4
North America pharmaceutical distribution & services $ (231) (71) (231) (71) 1
International pharmaceutical distribution & services $ (234) (77) (234) (77) 1
Medical- Surgical distribution & services Total Distribution Solutions $ (283) (81) (283) (81) 1

Change
As Adjusted Adjusted Constant Const
Revenues Distribution Solutions $ 1,174 (1) (1) 4
North America pharmaceutical distribution & services $ 1,174 (1) (1) 4
International pharmaceutical distribution & services $ 1,174 (1) (1) 4
Medical- Surgical distribution & services Total Distribution Solutions $ 1,174 (1) (1) 4
For information relating to the Adjusted Earnings (Non-GAAP) definitions, refer to the section entitled "Supplemental Non-GAAP Financial Information" of this release.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$ 96,307</td>
<td>$ 96,307</td>
<td>$ 87,636</td>
<td>$ 87,636</td>
<td>$ 82,876</td>
<td>$ 82,876</td>
<td>$ 82,876</td>
<td>$ 82,876</td>
</tr>
</tbody>
</table>

**GROSS PROFIT**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution Solutions (1)</td>
<td>$ 4,951</td>
<td>$ 183</td>
<td>$ 5,134</td>
<td>$ 4,874</td>
<td>$ 192</td>
<td>$ 5,066</td>
<td>$ 275</td>
</tr>
<tr>
<td>Technology Solutions (2)</td>
<td>741</td>
<td>744</td>
<td>722</td>
<td>727</td>
<td>(3)</td>
<td>738</td>
<td>(3)</td>
</tr>
<tr>
<td>Gross profit</td>
<td>$ 5,692</td>
<td>$ 186</td>
<td>$ 5,878</td>
<td>$ 5,596</td>
<td>$ 197</td>
<td>$ 5,793</td>
<td>$ 272</td>
</tr>
</tbody>
</table>

**OPERATING EXPENSES**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution Solutions (3)</td>
<td>($3,137)</td>
<td>$260</td>
<td>($2,877)</td>
<td>($3,378)</td>
<td>$334</td>
<td>($3,044)</td>
<td>$242</td>
</tr>
<tr>
<td>Corporate</td>
<td>(232)</td>
<td>1</td>
<td>(231)</td>
<td>(219)</td>
<td>10</td>
<td>(209)</td>
<td>(1)</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>($3,807)</td>
<td>$278</td>
<td>($1,529)</td>
<td>($4,128)</td>
<td>$365</td>
<td>($3,763)</td>
<td>($248)</td>
</tr>
</tbody>
</table>

**OTHER INCOME, NET**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution Solutions</td>
<td>$22</td>
<td>$2</td>
<td>$24</td>
<td>$34</td>
<td>$-</td>
<td>$34</td>
<td>$3</td>
</tr>
<tr>
<td>Technology Solutions</td>
<td>-</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>Corporate</td>
<td>7</td>
<td>-</td>
<td>7</td>
<td>5</td>
<td>-</td>
<td>5</td>
<td>-</td>
</tr>
<tr>
<td>Other income, net</td>
<td>$30</td>
<td>$2</td>
<td>$32</td>
<td>$41</td>
<td>$-</td>
<td>$41</td>
<td>$3</td>
</tr>
</tbody>
</table>

**OPERATING PROFIT**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution Solutions (2)</td>
<td>$1,836</td>
<td>$445</td>
<td>$2,281</td>
<td>$1,530</td>
<td>$526</td>
<td>$2,056</td>
<td>$36</td>
</tr>
<tr>
<td>Technology Solutions (4)</td>
<td>304</td>
<td>20</td>
<td>324</td>
<td>193</td>
<td>26</td>
<td>219</td>
<td>(8)</td>
</tr>
<tr>
<td>Corporate</td>
<td>2,140</td>
<td>465</td>
<td>2,605</td>
<td>1,723</td>
<td>552</td>
<td>2,275</td>
<td>28</td>
</tr>
<tr>
<td>Interest Expense</td>
<td>(180)</td>
<td>-</td>
<td>(180)</td>
<td>(191)</td>
<td>-</td>
<td>(191)</td>
<td>(5)</td>
</tr>
<tr>
<td>Income from continuing operations before income taxes</td>
<td>$1,756</td>
<td>$466</td>
<td>$2,201</td>
<td>$1,318</td>
<td>$562</td>
<td>$1,880</td>
<td>$22</td>
</tr>
</tbody>
</table>

**STATISTICS**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution Solutions</td>
<td>1.94 %</td>
<td>2.40 %</td>
<td>1.78 %</td>
<td>2.39 %</td>
<td>1.92 %</td>
<td>2.39 %</td>
<td>16 %</td>
</tr>
<tr>
<td>Technology Solutions</td>
<td>20.86</td>
<td>22.24</td>
<td>12.55</td>
<td>14.24</td>
<td>20.23</td>
<td>21.60</td>
<td>831</td>
</tr>
</tbody>
</table>

(1) Fiscal year 2016 reflects $59 million of cash proceeds representing our share of antitrust legal settlements.
(2) Fiscal year 2015 reflects a non-cash pre-tax charge of $34 million primarily relating to depreciation and amortization expense due to the reclassification of the workforce business within our International Technology business from discontinued operations to continuing operations. The charge was primarily recorded in cost of sales.
(3) Fiscal year 2016 includes a pre-tax gain of $51 million ($29 million after-tax) recognized from the sale of our ZEE Medical business.
(4) Fiscal year 2016 includes a pre-tax gain of $51 million ($38 million after-tax) recognized from the sale of our nurse triage business.

For more information relating to the Adjusted Earnings (Non-GAAP) and Constant Currency (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.

Schedule 4A

MCKESSON CORPORATION

RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) - BY ADJUSTMENT TYPE

(unaudited)

(in millions)

<table>
<thead>
<tr>
<th></th>
<th>Quarter Ended September 30, 2015</th>
<th>Quarter Ended September 30, 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corporate &amp; Distribution Solutions</td>
<td>Corporate &amp; Distribution Solutions</td>
<td>Corporate &amp; Distribution Solutions</td>
</tr>
<tr>
<td>Technology Solutions</td>
<td>Technology Solutions</td>
<td>Technology Solutions</td>
</tr>
<tr>
<td>Interest Expense</td>
<td>Total</td>
<td>Total</td>
</tr>
</tbody>
</table>

As Reported (GAAP):
Revenues $48,040 $721 $ - $48,761 $43,390 $770 $ - $44,160
Income from continuing operations before interest expense and income taxes (1) $926 $146 $ (101) $971 $790 $125 $ (106) $809

**Pre-Tax Adjustments:**

- Amortization of acquisition-related intangibles $98 $11 $ - $109 $117 $13 $ - $130
- Acquisition expenses and related adjustments $33 - - $33 $58 1 3 $62
- Claim and litigation reserve adjustments - - - - - - -
- LIFO-related adjustments 91 - - 91 94 - - 94
Total pre-tax adjustments $222 $11 $ - $233 $269 $14 $3 $286

**Adjusted Earnings (Non-GAAP):**

<table>
<thead>
<tr>
<th>Revenues</th>
<th>$48,040</th>
<th>$721</th>
<th>$ -</th>
<th>$48,761</th>
<th>$43,390</th>
<th>$770</th>
<th>$ -</th>
<th>$44,160</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income from continuing operations before interest expense and income taxes (1)</td>
<td>$1,148</td>
<td>$157</td>
<td>(101)</td>
<td>$1,204</td>
<td>$1,059</td>
<td>$139</td>
<td>(103)</td>
<td>$1,095</td>
</tr>
</tbody>
</table>

---

(1) Fiscal year 2016 includes a pre-tax gain of $51 million ($33 million after-tax) recognized from the sale of our ZEE Medical business within our Distribution Solutions segment.

For more information relating to the Adjusted Earnings (Non-GAAP) definition, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.

---

**Schedule 4B**

**RECONCILIATION OF GAAP SEGMENT FINANCIAL RESULTS TO ADJUSTED EARNINGS (NON-GAAP) - BY ADJUSTMENT TYPE**

(unaudited)  
(in millions)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Distribution Solutions</td>
<td>Technology Solutions</td>
<td>Corporate &amp; Interest Expense</td>
<td>Total</td>
<td>Distribution Solutions</td>
<td>Technology Solutions</td>
<td>Corporate &amp; Interest Expense</td>
<td>Total</td>
</tr>
<tr>
<td>As Reported (GAAP): Revenues</td>
<td>$94,850</td>
<td>$1,457</td>
<td>$ -</td>
<td>$96,307</td>
<td>$86,098</td>
<td>$1,538</td>
<td>$ -</td>
<td>$87,636</td>
</tr>
<tr>
<td>Income from continuing operations before interest expense and income taxes (1) (2) (3) (4)</td>
<td>$1,836</td>
<td>$304</td>
<td>(225)</td>
<td>$1,915</td>
<td>$1,530</td>
<td>$193</td>
<td>(214)</td>
<td>$1,509</td>
</tr>
<tr>
<td>Pre-Tax Adjustments: Amortization of acquisition-related intangibles</td>
<td>$201</td>
<td>$20</td>
<td>$ -</td>
<td>$221</td>
<td>$234</td>
<td>$25</td>
<td>$ -</td>
<td>$259</td>
</tr>
<tr>
<td>Acquisition expenses and related adjustments</td>
<td>$62</td>
<td>-</td>
<td>1</td>
<td>$63</td>
<td>$100</td>
<td>1</td>
<td>10</td>
<td>$111</td>
</tr>
<tr>
<td>Claim and litigation reserve adjustments</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LIFO-related adjustments</td>
<td>182</td>
<td>-</td>
<td>-</td>
<td>182</td>
<td>192</td>
<td>-</td>
<td>-</td>
<td>192</td>
</tr>
<tr>
<td>Total pre-tax adjustments</td>
<td>$445</td>
<td>$20</td>
<td>$1</td>
<td>$466</td>
<td>$526</td>
<td>$26</td>
<td>$10</td>
<td>$562</td>
</tr>
<tr>
<td>Adjusted Earnings (Non-GAAP): Revenues</td>
<td>$94,850</td>
<td>$1,457</td>
<td>$ -</td>
<td>$96,307</td>
<td>$86,098</td>
<td>$1,538</td>
<td>$ -</td>
<td>$87,636</td>
</tr>
<tr>
<td>Income from continuing operations before interest expense and income taxes (1) (2) (3) (4)</td>
<td>$2,281</td>
<td>$324</td>
<td>(224)</td>
<td>$2,381</td>
<td>$2,056</td>
<td>$219</td>
<td>(204)</td>
<td>$2,071</td>
</tr>
</tbody>
</table>

---

(1) Fiscal year 2016 reflects $59 million of cash proceeds representing our share of antitrust legal settlements within our Distribution Solutions segment.
(2) Fiscal year 2015 reflects a non-cash pre-tax charge of $34 million primarily relating to depreciation and amortization expense due to the reclassification of the workforce business within our International Technology business from discontinued operations to continuing operations. The charge was primarily recorded in cost of sales.
(3) Fiscal year 2016 includes a pre-tax gain of $51 million ($29 million after-tax) recognized from the sale of our ZEE Medical business within our Distribution Solutions segment.
(4) Fiscal year 2016 includes a pre-tax gain of $51 million ($38 million after-tax) recognized from the sale of our nurse triage business within our Technology Solutions segment.

For more information relating to the Adjusted Earnings (Non-GAAP) definition, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
**Schedule 5**

McKesson Corporation
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions)

<table>
<thead>
<tr>
<th></th>
<th>September 30, 2015</th>
<th>March 31, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ASSETS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current Assets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$ 5,359</td>
<td>$ 5,341</td>
</tr>
<tr>
<td>Receivables, net</td>
<td>16,798</td>
<td>15,914</td>
</tr>
<tr>
<td>Inventories, net</td>
<td>15,587</td>
<td>14,296</td>
</tr>
<tr>
<td>Prepaid expenses and other</td>
<td>1,005</td>
<td>1,119</td>
</tr>
<tr>
<td>Total Current Assets</td>
<td>38,749</td>
<td>36,670</td>
</tr>
<tr>
<td>Property, Plant and Equipment, Net</td>
<td>2,108</td>
<td>2,045</td>
</tr>
<tr>
<td>Goodwill</td>
<td>9,811</td>
<td>9,817</td>
</tr>
<tr>
<td>Intangible Assets, Net</td>
<td>3,254</td>
<td>3,441</td>
</tr>
<tr>
<td>Other Assets</td>
<td>1,897</td>
<td>1,897</td>
</tr>
<tr>
<td>Total Assets</td>
<td>$ 55,819</td>
<td>$ 53,870</td>
</tr>
</tbody>
</table>

| **LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND EQUITY** |         |                |
| Current Liabilities                  |         |                |
| Drafts and accounts payable         | $ 27,151 | $ 25,166       |
| Short-term borrowings                | 142     | 135            |
| Deferred revenue                     | 807     | 1,078          |
| Deferred tax liabilities             | 1,915   | 1,820          |
| Current portion of long-term debt    | 1,110   | 1,529          |
| Other accrued liabilities            | 3,650   | 3,769          |
| Total Current Liabilities            | 34,775  | 33,497         |
| Long-Term Debt                       | 8,136   | 8,180          |
| Other Noncurrent Liabilities         | 2,625   | 2,722          |
| Redeemable Noncontrolling Interests  | 1,410   | 1,386          |
| McKesson Corporation Stockholders' Equity | 8,788  | 8,001          |
| Noncontrolling Interests             | 85      | 84             |
| Total Equity                         | 8,873   | 8,085          |
| Total Liabilities, Redeemable Noncontrolling Interests and Equity | $ 55,819 | $ 53,870 |

**Schedule 6**

McKesson Corporation
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in millions)

<table>
<thead>
<tr>
<th></th>
<th>Six Months Ended September 30, 2015</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2014</td>
</tr>
<tr>
<td><strong>OPERATING ACTIVITIES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net income</td>
<td>$ 1,219</td>
<td>$ 888</td>
</tr>
<tr>
<td>Adjustments to reconcile to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>451</td>
<td>538</td>
</tr>
<tr>
<td>Other deferred taxes</td>
<td>23</td>
<td>114</td>
</tr>
<tr>
<td>Share-based compensation expense</td>
<td>78</td>
<td>82</td>
</tr>
<tr>
<td>LIFO charges</td>
<td>182</td>
<td>192</td>
</tr>
<tr>
<td>Gain from sale of businesses</td>
<td>(102)</td>
<td>(6)</td>
</tr>
<tr>
<td>Other non-cash items</td>
<td>7</td>
<td>24</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities, net of acquisitions:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receivables</td>
<td>(2,037)</td>
<td>(1,535)</td>
</tr>
<tr>
<td>Inventories</td>
<td>(1,469)</td>
<td>(1,122)</td>
</tr>
<tr>
<td>Drafts and accounts payable</td>
<td>1,960</td>
<td>1,463</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(258)</td>
<td>(253)</td>
</tr>
<tr>
<td>Taxes</td>
<td>203</td>
<td>(66)</td>
</tr>
<tr>
<td>Other</td>
<td>(6)</td>
<td>(158)</td>
</tr>
<tr>
<td>Net cash provided by operating activities</td>
<td>1,251</td>
<td>145</td>
</tr>
</tbody>
</table>

| **INVESTING ACTIVITIES** |   |   |
| Property acquisitions   | (178) | (190) |
| Capitalized software expenditures | (96) | (88) |
| Acquisitions, less cash and cash equivalents acquired | (11) | (31) |
### Supplemental Non-GAAP Financial Information

In an effort to provide investors with additional information regarding the company’s financial results as determined by generally accepted accounting principles ("GAAP"), McKesson Corporation (the "Company" or "we") also presents the following non-GAAP measures in this press release. The Company believes the presentation of non-GAAP measures provides useful supplemental information to investors with regard to its core operating performance, as well as assists with the comparison of its past financial performance to the Company’s future financial results. Moreover, the Company believes the presentation of non-GAAP measures assists investors’ ability to compare its financial results to those of other companies in the same industry. However, the Company's non-GAAP measures used in the press tables may be defined and calculated differently by other companies in the same industry.

- **Adjusted Earnings (Non-GAAP)**: We define Adjusted Earnings as GAAP income from continuing operations, excluding amortization of acquisition-related intangible assets, acquisition expenses and related adjustments, certain claim and litigation reserve adjustments, and Last-In-First-Out ("LIFO") inventory-related adjustments, as well as the related income tax effects. The Company evaluates its definition of Adjusted Earnings on a periodic basis and will update the definition from time to time. The evaluation considers both the quantitative and qualitative aspect of the Company’s presentation of Adjusted Earnings. A reconciliation of McKesson Corporation’s GAAP Financial Results to Adjusted Earnings (Non-GAAP) is provided in Schedules 2, 3 and 4 of the financial statement tables included with this release.

### Amortization of Acquisition-Related Intangibles

Amortization expense of acquired intangible assets purchased in connection with business acquisitions by the Company.

### Constant Currency

Constant Currency (Non-GAAP): To present our financial results on a constant currency basis, we convert current year period results of our operations in foreign countries, which are recorded in local currencies, into U.S. dollars by applying the average foreign currency exchange rates of the comparable prior year period. To present Adjusted Earnings per diluted share on a constant currency basis, we estimate the impact of foreign currency rate fluctuations on the Company’s non-controlling interests and adjusted income tax expense, which may vary from quarter to quarter. The supplemental constant currency information of the Company’s GAAP financial results and Adjusted Earnings (Non-GAAP) is provided in Schedule 3 of the financial statement tables included with this release.

The Company internally uses non-GAAP financial measures in connection with its own financial planning and reporting processes. Specifically, Adjusted Earnings serves as one of the measures management utilizes when allocating resources, deploying capital and assessing business performance and employee incentive compensation. The Company conducts its business worldwide in local currencies, including Euro, British pound and Canadian dollar. As a result, the comparability of our results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. We present constant currency information to provide a framework for assessing how our business performed excluding the estimated effect of foreign currency exchange rate fluctuations.

### Euro to U.S. Dollar Average Foreign Exchange Rates by Quarter

Our international pharmaceutical distribution and services business reflects the results from Celesio AG ("Celesio"). Celesio independently reports its financial results in Euros. Our financial results for the second quarter and first six months of fiscal 2016, as presented on a constant currency basis, exclude primarily the effects of the Euro to the U.S. dollar exchange rate fluctuations between the current periods and the comparable periods previously reported.

### Table: Euro to U.S. Dollar Exchange Rates

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Fiscal 2015</th>
<th>Fiscal 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Quarter</td>
<td>1.37</td>
<td>1.10</td>
</tr>
<tr>
<td>Second Quarter</td>
<td>1.33</td>
<td>1.11</td>
</tr>
<tr>
<td>Third Quarter</td>
<td>1.25</td>
<td>1.10**</td>
</tr>
<tr>
<td>Fourth Quarter</td>
<td>1.13</td>
<td>1.10**</td>
</tr>
</tbody>
</table>

* Quarterly exchange rates are computed as a simple average using the average monthly Euro to U.S. dollar exchange rate as reported by the European Central Bank.

** McKesson Corporation’s full year guidance exchange rate as communicated on May 12, 2015, July 29, 2015 and October 29, 2015.

### Language:

English

### Contact:

McKesson Corporation
Erin Lampert, 415-983-8391 (Investors and Financial Media)
Erin.Lampert@McKesson.com

Wes Fortner, 415-983-8392 (Talent and Business Media)
Wes.Fortner@McKesson.com

### Ticker Slug:

Ticker: MCK
Exchange: NYSE

### Source URL:


### Links:

[1](http://www.businesswire.com)
[4](mailto:Erin.Lampert@McKesson.com)
[5](mailto:Wes.Fortner@McKesson.com)